Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: CNS tumours

280O - Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results

Date

09 Sep 2022

Session

Proffered Paper session: CNS tumours

Topics

Targeted Therapy

Tumour Site

Central Nervous System Malignancies

Presenters

John de Groot

Citation

Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047

Authors

P. Wen1, J.F. de Groot2, J. Battiste3, S. Goldlust4, D. Damek5, B. Ellingson6, J. Garner7, J. Friend7, J. Simpson7, A. Olivero8, T. Cloughesy9

Author affiliations

  • 1 Center For Neuro-oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 2 Neuro-oncology Department, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 3 Neuro-oncology Department, Stephenson Cancer Center/University of Oklahoma, 73104 - Oklahoma City/US
  • 4 Neuro-oncology Department, John Theurer Cancer Center - Hackensack University Medical Center, 07601 - Hackensack/US
  • 5 Neuro-oncology Department, UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, 80045 - Aurora/US
  • 6 Center For Computer Vision And Imaging Biomarkers, Department Of Radiological Sciences, UCLA Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles, 90095 - Los Angeles/US
  • 7 Clinical Research, Kazia Therapeutics Limited, 2000 - Sydney/AU
  • 8 Clinical Research, Olivero Consulting, 94019 - Half Moon Bay/US
  • 9 Department Of Neurology, Ronald Reagan UCLA Medical Center University of California, 90095 - Los Angeles/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 280O

Background

Paxalisib is being developed for the treatment of glioblastoma multiforme (GBM). Post hoc analysis of phase 1 fluorodeoxyglucose-positron emission tomography (FDG-PET) scans suggested that paxalisib crosses the blood-brain barrier with a uniform distribution throughout the brain.

Methods

The recently completed phase 2 trial (NCT03522298) enrolled patients with newly diagnosed GBM with unmethylated MGMT promoter status following surgical resection and chemotherapy (Stupp Regimen). Study outcomes comprised maximum tolerated dose (MTD), safety, preliminary efficacy, pharmacokinetics (PK) at the MTD under fed and fasted conditions and change in FDG-PET uptake in patients with measurable disease.

Results

Patients (n=30; 70.0% males, mean age 58.5 years) received between 1 and 29 treatment cycles. At the MTD (60 mg/day), paxalisib prolonged median progression free survival (8.4 months [RANO], 8.6 months [mRANO]) and improved median overall survival (15.7 months). Paxalisib was steadily absorbed (median Tmax 2.5 and 4 hours postdose) and declined with a mean elimination half-life ranging from 20.2 to 29.0 hours. Mean half-life (20.2 to 29.0 hours) was similar across dose levels and under fed and fasted conditions. Systemic exposure to paxalisib appeared slightly higher for the 60 mg fed status compared to 60 mg fasted status. Comparison of fed versus fasted treatment was statistically significant for Cmax at the 90% level (geometric least squares mean ratios: AUC0-last 1.33, AUC0-inf 1.06, and Cmax 1.52). Ten patients underwent FDG-PET imaging, 8 (80%) had a decrease in FDG uptake on Day 3 and/or Day 7 in Cycle 1 and 4 (40%) had a metabolic partial response.

Conclusions

PK parameters were consistent with prior clinical experience and there was no evidence of a deviation from dose-proportionality. At the MTD FDG-PET data provide evidence that paxalisib has the ability to exert biological effect in tumour tissue, irrespective of fed or fasted status. Further evaluation is ongoing in GBM AGILE (NCT03970447).

Clinical trial identification

NCT03522298.

Editorial acknowledgement

Hazel Palmer ISMP CMPP, Scriptix Pty Ltd., Sydney, NSW, Australia.

Legal entity responsible for the study

Kazia Therapeutics Limited.

Funding

Kazia Therapeutics Limited.

Disclosure

P. Wen: Financial Interests, Personal, Advisory Role: Agios, AstraZeneca, Vascular Biogenics, VBI Vaccines, Tocagen, Bayer, Blue Earth Diagnostics, Karyopharm Therapeutics, Voyager Therapeutics, QED Therapeutics, Imvax, ElevateBio, Integral Health, Prelude Therapeutics, Novocure, Mundipharma, Black Diamond Therapeutics, Day One Biopharmaceuticals, Sapience Therapeutics, Nuvation Bio, Celularity, Novartis, Merck, Boston Pharmaceuticals, Chimerix; Financial Interests, Institutional, Funding, Research Funding: Agios, AstraZeneca, Merck, Novartis, Oncoceutics, Lilly, Beigene, Kazia Therapeutics, MediciNova, Vascular Biogenics, VBI Vaccines, Puma Biotechnology, Celgene, Bayer, Nuvation Bio, Chimerix, Karyopharm Therapeutics. J.F. de Groot: Other, Personal, Full or part-time Employment, Recipient is Immediate Family Member: ZIOPHARM Oncology; Financial Interests, Personal, Advisory Role: Genetech/Roche, AbbVie, Merck, Mundipharma Research, GenomiCare, KIYATEC, resTORbio, Janssen, Bioasis Technologies, InSightec, DelMar Pharmaceuticals, Samus Therapeutics, Magnolia Innovation, Karyopharm Therapeutics, Prelude Therapeutics, Cure Brain Cancer Foundation, Sapience Therapeutics, GlaxoSmithKline, Tocagen, Voyager Therapeutics, Novartis, Debiopharm Group, Agios, Monteris Medical; Other, Personal, Leadership Role, Recipient is Immediate Family Member: ZIOPHARM Oncology; Financial Interests, Personal, Other: VBI Vaccines; Financial Interests, Personal, Stocks/Shares: Gilead Sciences, WuXi Biologics; Other, Personal, Ownership Interest, Recipient is Immediate Family Member: ZIOPHARM Oncology; Financial Interests, Personal, Funding, Research funding: CarThera, Haihe Pharmaceutical, Taiho Pharmaceutical. J. Battiste: Financial Interests, Personal, Other: SVN Med. S. Goldlust: Financial Interests, Personal, Full or part-time Employment: Regional Cancer Care Associates; Financial Interests, Personal, Advisory Role: NovoCure, Boston Biomedical, Sumitomo Dainippon Pharma Oncology, Cellevolve; Financial Interests, Personal, Leadership Role: Cellevolve; Financial Interests, Personal, Speaker’s Bureau: NovoCure; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: NovoCure, Caris Life Sciences, Kyowa Kirin International; Financial Interests, Personal, Stocks/Shares: COTA; Financial Interests, Personal, Other, Honoraria: Cornerstone Specialty Network, Daiichi Sankyo/AstraZeneca, Physicans' Education Resource; Financial Interests, Institutional, Funding, Research Funding: NovoCure, Celldex, Cortice Biosciences, Acerta Pharma, Bristol Myers Squibb, Tocagen, Wex Pharmaceuticals, Northwest Biotherapeutics, AbbVie, Celgene, Boston Biomedical, Cantex Pharmaceuticals, Diffusion Pharmaceuticals, Amgen, CNS Healthcare, Karyopharm Therapeutics, Novogen, Pfizer, Sanofi, Kazia Therapeutics, Imvax, Merck, Regeneron, Boehringer Ingelheim, Ono Pharmaceutical, Sumitomo Dainippon Pharma Oncology, Celularity; Financial Interests, Institutional, Funding, Research fundingResearch Funding: ImmunoCellular Therapeutics. D. Damek: Financial Interests, Institutional, Funding, Research Funding: Kazia Therapeutics, NovoCure. B. Ellingson: Financial Interests, Personal, Advisory Role: Siemens, Medicenna, MedQIA, Imaging Endpoints, Neosoma, Kazia Therapeutics, VBL Therapeutics, Global Coalition for Adaptive Research, Servier, Janssen, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris Medical, Alpheus Medical; Financial Interests, Personal, Funding, Research funding: Siemens, Jansssen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Siemens. J. Garner: Financial Interests, Personal, Full or part-time Employment: Kazia Therapeutics; Financial Interests, Personal, Leadership Role: Kazia Therapeutics; Financial Interests, Personal, Stocks/Shares: Kazia Therapeutics. J. Friend: Financial Interests, Personal, Full or part-time Employment: Helsinn Therapeutics, Kazia Therapeutics; Financial Interests, Personal, Leadership Role: Helsinn Therapeutics, Kazia Therapeutics; Financial Interests, Personal, Stocks/Shares: Kazia Therapeutics. J. Simpson: Financial Interests, Personal, Full or part-time Employment: Kazia Therapeutics; Financial Interests, Personal, Leadership Role: Kazia Therapeutics; Financial Interests, Personal, Stocks/Shares: Kazia Therapeutics. A. Olivero: Financial Interests, Personal, Advisory Role: Genentech/Roche, ORIC Pharmaceuticals, Imugene, Kazia Therapeutics, Genentech; Financial Interests, Personal, Royalties, Has patents fro employment with Genentech/Roche: Genentech/Roche; Financial Interests, Personal, Stocks/Shares: Roche, Kazia Therapeutics; Financial Interests, Personal, Full or part-time Employment: Genentech; Financial Interests, Personal, Leadership Role: Genentech; Financial Interests, Personal, Other, Research funding in the form of medical writing support, furnished by Daniel Clyde, PhD, of Health Interactions,: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Kazia Therapeutics, Genentech. T. Cloughesy: Financial Interests, Personal, Advisory Role: Roche/Genentech, Tocagen, VBL Therapeutics, Novartis, Agios, AbbVie, Pfizer, Bristol Myers Squibb, Merck, GW Pharmaceuticals, Boehringer Ingelheim, KIYATEC, VBI Vaccines, Bayer, DelMar Pharmaceuticals, QED Therapeutics, Amgen, Pascal Biosciences, Karyopharm Therapeutics, Katmai Pharmaceuticals, Global Coalition for Adaptive Research, DNAtrix, Inovio Pharmaceuticals, Sapience Therapeutics; Financial Interests, Personal, Royalties, U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US: UCLA; Financial Interests, Personal, Other: Global Coalition for Adaptive Research, Break Through Cancer; Financial Interests, Personal, Stocks/Shares: Notable Labs, Katmai Pharmaceuticals, Chimerix.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.